# A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

> **NCT07735637** · PHASE3 · NOT_YET_RECRUITING · sponsor: **AstraZeneca** · enrollment: 750 (estimated)

## Conditions studied

- Newly Diagnosed Multiple Myeloma (NDMM)

## Interventions

- **BIOLOGICAL:** AZD0120
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Melphalan (part of ASCT)
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT07735637
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-25
- **Primary completion:** 2028-10-11
- **Final completion:** 2039-11-09
- **Target enrollment:** 750 (ESTIMATED)
- **Last updated:** 2026-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07735637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07735637, "A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07735637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*